๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Harbin
Clinical trial register · China

Clinical Trials in Harbin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Harbin Medical University24 AstraZeneca24 Eli Lilly and Company20 Hoffmann-La Roche16 Bristol-Myers Squibb16
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Harbin

545 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
NCT05918094Gastric Cancer
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Active, closed
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252Non-small Cell Lung Cancer
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
NCT06202261Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
154
Chongqing, Harbin
2023-04-13
Recruiting
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
NCT05590871Hypertension
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
SeQuent ยฎ Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
NCT06010342Solid Tumor
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Active, closed
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Active, closed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
BeiGene
Phase 2
400
Hefei, Beijing, Fuzhou, Baoding, Harbin, Zhengzhou, Wuhan, Nantong
2023-03-07
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
NCT05768503Metastatic Microsatellite-stable Colorectal Cancer
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Recruiting
Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment
NCT06342661Cerebrovascular Disease Small Vessel
First Affiliated Hospital of Harbin Medical University
Observational
400
Harbin
2023-03-01
Recruiting
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
NCT05607498Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Phase 1
150
Changsha, Baoding, Beijing, Bengbu, Guangzhou, Harbin, Shandong, Tianjin
2023-03-01
Active, closed
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
NCT05557838Hepatocellular Carcinoma
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection๏ผˆBROAD๏ผ‰
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
NCT05038150Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Shanghai, Chengdu
2023-01-16
Recruiting
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.
NCT06927349Advanced Solid Tumours
Shandong Boan Biotechnology Co., Ltd
Phase 1
70
Harbin
2023-01-11
Recruiting
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
NCT05653453Locally Advanced Pancreatic Cancer
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 3
512
Harbin, Jinan, Shanghai
2022-12-20
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Changsha
2022-12-14
Recruiting
Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases
NCT05965128Respiratory Infectious Diseases
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Recruiting
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Recruiting
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
NCT05494190Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Not applicable
111
Harbin, Jinan, Shanghai
2022-11-01
Recruiting
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
NCT05579132Acute Lymphoblastic Leukemia
MSD R&D (China) Co., Ltd.
Phase 1/2
203
Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu
2022-11-01
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Beijing, Changchun, Changping, Chengdu, Chongqing, Haikou, Harbin, Hengshui Shi
2022-10-11
Recruiting
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961Breast Cancer
InventisBio Co., Ltd
Phase 3
640
Beijing, Harbin
2022-09-15
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
GlaxoSmithKline
Phase 3
109
Beijing, Changsha, Guangzhou, Harbin, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566Non-small Cell Lung Cancer
Teligene US
Phase 2
99
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Recruiting
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
NCT05276726Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
NCT05410145KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
442
Hefei, Beijing, Guangzhou, Hangzhou, Harbin, Wuhan, Changsha, Zhengzhou
2022-08-03
Active, closed
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
NCT05502393Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
133
Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin
2022-07-26
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871Breast Cancer, Head and Neck Cancer
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Active, closed
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT05918133TNBC
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 3
95
Fuzhou, Guangzhou, Harbin, Changsha, Shengyang, Jinan, Hangzhou, Beijing
2022-06-15
Active, closed
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05879068SCLC
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Not yet open
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT05367765CML, Chronic Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4
2,400
Harbin
2022-04-30
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT05239741Colorectal Neoplasms
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
By invitation
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT06707922Chronic Hepatitis B
Xiamen Amoytop Biotech Co., Ltd.
Not applicable
350
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei
2022-03-18
Active, closed
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
NCT05257395Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3
397
Harbin
2022-03-14
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Active, closed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537Age-Related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
170
Harbin, Tianjin, Shanghai
2022-02-17
Recruiting
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058HER2-positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
Phase EARLY_PHASE1
150
Hefei, Beijing, Guangzhou, Nanning, Shijiazhuang, Harbin, Anyang, Zhengzhou
2022-01-21
Recruiting
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
NCT05498974Type1diabetes, Diabetes
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Active, closed
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT05112965Neoplasms
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
Study of Sacituzumab Govitecan in Patients With Solid Tumor
NCT05119907Solid Tumor
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922Ovarian Cancer, Recurrent Cancer
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
Beijing, Harbin, Wuhan
2021-09-27
Active, closed
A Clinical Effectiveness Study of Total Laparoscopic Subcutaneous Gland Resection Combined With Nipple-Areola Complex Lift in the Management of Moderate to Severe Gynecomastia in Males
NCT07314086Gynecomastia
First Affiliated Hospital of Harbin Medical University
Observational
200
Harbin
2021-09-01
Active, closed
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
NCT04968028Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Shanghai Changzheng Hospital
Not applicable
167
Beijing, Shenzhen, Harbin, Jining, Qingdao, Shanghai, Taiyuan, Xiโ€™an
2021-08-17
Recruiting
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
NCT04136782Breast Cancer
Shengjing Hospital
Phase 4
110
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Recruiting
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
NCT04476485Breast Cancer
Shengjing Hospital
Observational
1,000
Harbin, Changchun, Dalian, Panjin, Shenyang
2021-07-19
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Active, closed
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)
NCT04765592Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
88
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming
2021-06-07
Recruiting
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
NCT04912518ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
Harbin Medical University
Not applicable
250
Hefei, Lanzhou, Harbin, Mudanjiang, Zhengzhou, Wuhan, Xi'an, Taiyuan
2021-05-27
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,854
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Active, closed
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
NCT04523272Advanced Renal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
528
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan
2020-08-25
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337Medullary Thyroid Cancer
Loxo Oncology, Inc.
Phase 3
291
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou
2020-02-11
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
Hoffmann-La Roche
Phase 2/3
325
Beijing, Changchun, Chongqing, Fujian, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-29
Recruiting
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Rows per page Showing 401–500 of 545
Previous 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/harbin?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 545 of those studies with a site in Harbin.

How many clinical trials are recruiting in Harbin?

308 of the 545 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 60 have not yet opened recruitment, 171 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.